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a set of independent risk factors. The key findings, relative risks and 95% confidence
intervals were calculated and are presented below.
Results:
Conclusion. The data demonstrate that in renal transplant patients traditional risk factors
such as age, diabetes, previous coronary heart disease and lipid values are major deter-
minants of cardiac risk. The analysis also demonstrates that renal function and rejection
episodes are independent risk factors for cardiac events.
1124-192 Rosiglitazone Reduces Novel Biomarkers of 
Cardiovascular Disease in Subjects With Type 2 
Diabetes Mellitus Already on Statin Therapy
John D. Brunzell, Santica Marcovina, Dahong Yu, Alexander Cobitz, Errol Gould, Hongzi 
Chen, Lisa Porter, University of Washington, Seattle, WA, GlaxoSmithKline, King of 
Prussia, PA
Cardiovascular disease (CVD) is the major cause of morbidity and mortality in type 2 dia-
betes (T2DM). Increased preponderance of small dense LDL particles and decreased
HDL are atherogenic factors associated with insulin resistance (IR) and the metabolic
syndrome. IR is also associated with hypercoagulable and proinflammatory states which
increase CVD risk. In T2DM, treatment with rosiglitazone (RSG) has demonstrated con-
version of the small dense LDL Type B phenotype (LDL Rf < 0.263) to the less athero-
genic Type A phenotype (LDL Rf > 0.263) as well as improvement in concentrations of
additional CVD biomarkers including CRP, PAI-1 and MMP-9. The effect of RSG on CVD
risks factors in T2DM subjects on statin therapy with predominately small dense LDL was
evaluated. Seventy two subjects on diet/exercise, or metformin monotherapy, who had
received at least 8 weeks of statin therapy, and had LDL Rf < 0.263 were randomized to
the addition of placebo (N=14) or RSG 4mg (N=29) or 8mg (N=29) TDD. Results: By
study end (Week 12), 24% (4mg) and 36% (8mg) of patients on RSG had converted to a
pattern of predominately large, buoyant LDL Rf (LDL Rf > 0.263) compared to no conver-
sion in the placebo group. Significant reductions in CRP and PAI-1 were observed in
RSG treated subjects. 
Conclusion: In T2DM subjects on statins, RSG significantly increased LDL particle size 
and reduced CRP and PAI-1, suggesting RSG may reduce CVD events.
1124-193 Dose of Fish Oil Needed to Achieve Cardioprotective 
Blood Levels of Omega-3 Fatty Acids
William S. Harris, Mid America Heart Institute, Kansas City, MO, University of Missouri-
Kansas City, Kansas City, MO
Background: The evidence for a cardioprotective effect of omega-3 fatty acids (FA) has
accumulated to the point where the American Heart Association (AHA) now recommends
that patients with known coronary heart disease (CHD) consume about 1 g/d of eicosap-
entaenoic and docosahexaenoic acids (EPA+DHA), and adults without disease should
eat at least two (preferably oily) fish meals per week. (The latter would provide about 500
mg/d EPA+DHA). Both epidemiological and interventional studies suggest that these
intakes will lower risk for death from CHD by 30%-50%. A variety of studies point to a red
blood cell (RBC) EPA+DHA level (hereafter, called the Omega-3 Index) of >=8% (percent
of total RBC FA) as a reasonable target value for cardioprotection. An Index of <=4% is
associated with relatively high risk. This study was undertaken to determine the effects of
AHA-recommended intakes of omega-3 FA from supplements on the Omega-3 Index.
Methods: Healthy subjects on stable background diets were randomized to supplementa-
tion with either 0 (placebo; n=22), 0.5 g (n=24), or 1.0 g (n=10) of EPA+DHA (ROPUFA-
30, Roche Vitamins). After five months, their Omega-3 Indexes were determined. Com-
pliance was determined by capsule count.
Results: Overall compliance was 95%, and it was not less than 75% for any subject. The
mean (SD) Omega-3 Indexes achieved were 4.3 (1.2%), 8.0 (1.7%), and 10.0 (2.8%),
respectively. Omega-3 Indexes of >=8% were achieved by 5%, 54%, and 80% of those
taking 0, 0.5g and 1.0 g/d, respectively. Indexes of <=4% were observed in 55%, 4% and
10% in each respective group.
Conclusions: These results suggest that most people taking 1 g EPA+DHA/d will achieve
or surpass the 8% target value for the Omega-3 Index, and that about half of those taking
500 mg/d will reach the 8% level. Thus, based upon blood levels likely achieved, AHA
recommended intakes should produce significant cardioprotection. The Omega-3 Index
identifies a risk factor that is easily, safely and inexpensively corrected and may represent
a novel, physiologically-relevant, independent and graded marker of risk for death from
CHD. (Sponsored in part by Roche Vitamins, Inc.).
1124-194 Metabolic Syndrome and Prevention of Premature 
Coronary Artery Disease
Ana Mari Schaper, Kwame Osei Akosah, Vicki Lynn McHugh, Sharon Ione Barnhart, 
Patricia A. Perlock, Troy Haider, Michelle Ann Mathiason, Gundersen Lutheran Health 
System, La Crosse, WI
Background: Metabolic Syndrome (MS) and primary prevention of coronary artery dis-
ease (CAD) is becoming increasingly appreciated. The National Cholesterol Education
Program (NCEP III) guidelines have defined MS and recommended aggressive manage-
ment. Consequently, an emphasis needs to be placed on the identification of persons
with MS. Lipoprotein subclass analysis allows for determination of atherogenic lipopro-
tein traits (ALT) of MS, but its incremental value remains unknown.
Objective: To determine the rate of MS in subjects screened for primary prevention and
to assess incremental value of ALT.
Methods: 254 young adults (women < age 65; men < 55) without known CAD, scheduled
for elective coronary angiogram had labs drawn for lipid and lipoprotein analysis (Lipo-
Science, Inc). MS per NCEP III was defined as the presence of >3 of the following traits:
low HDL (men <40 mg/dL; women <50 mg/dL), high triglyceride (> 150 mg/dL), hyperten-
sion (>130/85 mm Hg), fasting glucose (> 110 mg/dL), and BMI >30. ALT was defined as
>2 of the following values determined by nuclear magnetic resonance spectroscopy
(NMR): small LDL pattern B (< 20.5 nm), reduced large HDL (<11 mg/dL) and elevated
large VLDL (>27 mg/dL). CAD was defined as stenosis severity of > 50%
Results: Mean age was 53±8. 82% were overweight or obese. The mean total, LDL, and
HDL cholesterol levels were acceptable per NCEP III and not statistically different
between subjects with and without CAD. Mean triglyceride (170 versus 138 mg/dL,
p=0.002) and glucose (139 versus 109 mg/dL, p=0.005) were higher in those with CAD.
MS was present in 59 (24%) of participants. ALT was present in 85 (35%) of participants.
73 participants met criteria for CAD, of whom 26 (36%) had MS, and 35 (48%) had ALT.
The odds for MS in predicting CAD were 2.3 (CI: 1.3-4.2, p=0.006). The odds for ALT
were 2.2 (CI: 1.2-3.9, p=0.007). Using either criterion, as many as 43 (59%) of subjects
with CAD were identified (OR=2.6, CI: 1.5-4.5, p<0.001).
Conclusion: In a population of young adults with high levels of obesity and elevated trig-
lyceride, the use of both of these definitions provides incremental value in identifying
high-risk young adults who should be targeted for aggressive risk modification.
1124-195 Anthropomorphic Predictors of Insulin Sensitivity in a 
Healthy Population
Justo Sierra Johnson, Bruce D. Johnson, Kent R. Bailey, Stephen T. Turner, Mayo Clinic, 
Rochester, MN
Background: Insulin sensitivity (SI) is the capability of insulin to increase glucose dis-
posal. Abdominal fat distribution has been associated with insulin sensitivity. However, it
is not clear whether sophisticated measures (DEXA scanning) of body fat and fat distribu-
tion are better predictors of SI than simple measures (BMI, waist and hip circumferance,
waist-to-hip ratioWHR). Methods: We studied 256 healthy Caucasian subjects from
Rochester, MN (age 19-60, 133 women) who were admitted to the GCRC for measure-
ment of SI using the minimal model technique. All subjects had the simple and the
sophisticated measures of body fat distribution taken. Body fat measures were analyzed
and compared individually (controlling for age and gender) and in multiple regression
models, in relation to SI. Results: Among simple measures: waist circumferance and BMI
had the best correlations with SI (see Table), while the corresponding best predictors
among the DEXA measures were: head fat (raw and percent) and upper body fat. When
WHR and BMI were combined, or when head fat and upper body fat were combined, the
Risk factors at baseline (RR for) Univariate RR Multivariate RR
Age, years, 1 extra year 1.04 (1.02,1.05) 1.03 (1.01, 1.06)
Diabetes, Yes/No 2.35 (1.56, 2.35) 2.13 (1.32, 3.46)
Treatment for rejections, Yes/No 1.47 (1.00, 2.16) 1.5(1.01, 2.48)
Coronary heart disease, Yes/No 3.28 (2.08, 5.18) 2.11 (1.23, 3.62)
Total cholesterol, (1 extra mmol/L ) 1.31 (1.12, 1.55) 1.21 (0.97, 1.50)
LDL cholesterol (1 extra mmol/L ) 1.41 (1.18, 1.69) 1.34 (1.09, 1.66)
HDL Cholesterol (1extra mmol/L ) 0.55 (0.34, 0.90) 0.56 (0.31, 1.02)
Triglycerides (1extra mmol/L ) 1.11 (1.03, 1.19)
ST-T abnromalities, Yes/No 2.02 (1.32, 3.08)
Pulse Pressure (1 extra mmHg) 1.01 (1.00, 1.02)
Serum creatinine (10 extra umol/L) 1.05 (1.02, 1.08 1.05 (1.01, 1.09)
Aspirine use, Yes/No 1.65 (1.08, 2.54)
Placebo
N=14
RSG 4 mg
N=29
RSG 8 mg
N=29
% patients converted to
LDL Rf > 0.263 (%)
0 23.5 36*
Mean ∆ & %∆ (95% ci) from 
baseline:
LDL Rf -0.0003
(-0.0112, 0.0107)
0.011*
(0.0033, 0.0187)
0.014*
(0.0069, 0.0212)
CRP (%) 17.26
(-18.41, 68.50)
-35.38*
(-49.67, -17.05)
-39.08*
(-52.36, -22.10)
PAI-1 antigen (%) -22.69
(-42.12, 3.28)
-10.63
(-26.81, 9.13)
-22.65*
(-37.05, -4.96)
PAI-1 activity (%) -29.02
(-57.08, 17.38)
-17.30
(-41.45, 16.83)
-30.72*
(-51.14, -1.76)
MMP-9 (%) 20.13
(-14.59, 68.97)
-8.70
(-27.39, 14.79)
-17.76
(-34.44, 3.17)
* Statisticallysignificant
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R2 increased to 0.44 (P<0.05). Finally, a model which included WHR, Head fat, and
Upper Body fat yielded a maximal R2 of 0.47 (P<0.05), an improvement over either set of
measurements alone. Conclusion: Simple measures when used alone are as effective as
more sophisticated methods like DEXA for predicting SI in a healthy population. However,
when these measures are combined there is a small increased predictive power. 
1124-196 Impact of Elevated Age and Sex-Adjusted Body Mass 
Index in School Age Children on Insulin Resistance and 
Lipoprotein Subfractions
David K. Murdock, Karen Olson, Kirk Jenkins, Mary Roth, Sharon Fox, Patrick Hughes, 
Bryan Hendricks, Cardiovascular Research and Education Foundation, Inc, Wausau, WI, 
Community Health Care/Wausau Health Foundation, Wausau, WI
Background: The Wausau SCHOOL Project is a community-based effort to assess the
frequency of cardiovascular risk factors in students in the Wausau School District. Objec-
tive: Define the incidence of elevated BMI and determine its relationship to standard lipid
profiles, homeostatic model assessment of insulin resistance (HOMA-IR), LDL particle
size and number. Methods: Age and sex adjusted BMI (zBMI), fasting plasma insulin,
glucose levels and nuclear magnetic resonance lipid profiles (LipoScience®) was mea-
sured in 225 randomly selected students (110 in 2nd grade and 125 in 11th grade). Over-
weight was defined as zBMI > 85th centile based on 2000 CDC norms. Results: Over
31% of the students were classified as overweight. (30.6% in 2nd grade and 32.5% in
11th grade). HOMA-IR values were significantly higher for 11th graders than for 2nd grad-
ers (2.18±2.65 vs. 1.22± 1.07, p<0.01). HOMA-IR values were also significantly higher
for females than for males (2.04±2.66 vs. 1.33±0.94, p<0.05). Those with zBMI above the
85th centile had significantly higher levels of total cholesterol (182.0±34.0 vs. 170.2±28.5,
p<0.01), LDL (123.4±28.5 vs. 112.7±25.7, p<0.01), triglycerides (118.6±80.7 vs.
86.4±35.6, p<0.001), LDL particle number (1299.8±379.5 vs. 1135±248.0, p<0.001), and
HOMA-IR (2.61±3.47 vs. 1.32±0.09, p< 0.001), while HDL levels were lower (43.7±10.0
vs. 47.5 ±9.7, p<0.01). There were no significant differences in LDL particle size. Con-
clusions: A significant percentage of children and adolescents are overweight. IR
increases significantly with age and zBMI and is associated with an atherogenic lipid pro-
file characterized by an increase in the number of small LDL particles and TG levels and
lower HDL levels, similar to that seen in adults.
1124-197 Additive Gene-Gene Interaction Between CYP7A1 and 
Apolipoprotein E as Genetic Determinants of Low-
Density Lipoprotein Cholesterol-Lowering Response to 
Atorvastatin
Kouji Kajinami, Noboru Takekoshi, Margaret E. Brousseau, Jose M. Ordovas, Ernst J. 
Schaefer, Kanazawa Medical University, Uchinada, Japan, Tufts University, Boston, MA
Background: The mechanisms responsible for interindividual variation in response to sta-
tin therapy remain uncertain. Bile acid biosynthesis is one of the determinants of intracel-
lular cholesterol and, in turn, cholesterol synthesis rate in hepatocytes. This raises the
hypothesis that variation in the cholesterol 7α-hydroxylase gene (CYP7A1), a key
enzyme in bile acid biosynthesis, may influence the statin response. Methods and
Results:To test this hypothesis, we examined a promoter polymorphism (A–290C) in
CYP7A1 in 324 hypercholesterolemic patients treated with atorvastatin 10mg. The
CYP7A1 polymorphism was significantly and independently associated with poor LDL
cholesterol response. Mean reductions were -39% in wild type allele homozygotes, -37%
in variant allele heterozygotes, and -34% in variant allele homozygotes, respectively
(p<0.0001 for linear trend). The effects of this polymorphism were more striking in men
than in women and were enhanced by the coexistence of common variants of the apoli-
poprotein E gene (APOE), ε2 or ε4. In subjects having wild type alleles at both loci, the
mean reduction in LDL cholesterol was -40%, while in subjects having two CYP7A1 vari-
ant alleles and at least one variant APOE allele, the mean reduction in LDL cholesterol
was -31% (p<0.0001). In addition, combination analysis of these two polymorphsims
more accurately predicted the achievement of goal LDL cholesterol, than did both single
polymorphism analysis. Conclusions:The CYP7A1 A–290C promoter variant was signifi-
cantly and independently associated with poor response to atorvastatin. The effects of
this polymorphism were additively enhanced, when common variants in another locus,
APOE, coexist.
1124-198 Plasma Sphingomyelin Levels in Coronary Artery 
Disease: A Relationship With Serum Triglyceride and 
Apolipoprotein B and Other Risk Factors
Axel Schlitt, Stefan Blankenberg, Daoguang Yan, Hans von Gyzicki, Christoph Bickel, 
Karl Lackner, Juergen Meyer, Hans J. Rupprecht, Xian-Cheng Jiang, State University of 
New York, Downstate Medical Center, Brooklyn, NY, Johannes Gutenberg University, 
Mainz, Germany
Objective
Sphingomyelin (SM) is one of the major phospholipids in the cell membrane and in lipo-
proteins. In human plasma, SM is mainly found in atherogenic lipoproteins, thus, high lev-
els of SM may promote atherogenesis. 
Methods
To further evaluate the role of SM in atherosclerosis, we measured plasma SM levels in
1,102 patients with coronary artery disease (CAD) and 444 healthy controls.
Results
We demonstrated that plasma SM in CAD patients was significantly higher than in con-
trols (51.8 versus 44.9 mg/dl; p < 0.001). Logistic regression analysis showed that
plasma SM was significantly associated with incidence of CAD (OR: 4.9, 95% CI 3.4 –
7.0, for subjects in the fourth quartile in comparison to subjects in the first quartile).
Plasma SM levels showed a strongest and significant correlation with plasma apolipopro-
tein B (apoB)- (r=0.34, p < 0.001) and triglycerides -levels (r=0.31, p < 0.001) in all sub-
jects, respectively. The association between SM and incidence of CAD remained
independently significant after adjustment for most potential confounders including apoB
and triglyceride, such that patients within the fourth quartile of SM revealed a 6.0 fold
(95% CI 3.4 – 7.0) increase of risk.
Conclusion
These results reveal that the proatherogenic potency of human plasma SM levels, as
shown in this study by significantly elevated levels of SM in patients, could be related to
abnormal apoB -containing or triglyceride -rich lipoprotein metabolism.
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841-1 Ceramide Triggers Weibel-Palade Body Exocytosis
Rinky Bhatia, Kenji Matsushita, Munekazu Yamakuchi, Craig Morrell, Charles J. 
Lowenstein, Johns Hopkins University School of Medicine, Baltimore, MD
Background: The sphingolipid ceramide mediates a variety of stress responses, including
vascular inflammation and thrombosis. Activated endothelial cells release Weibel-Palade
bodies, granules containing vWF and P-selectin, which induce leukocyte rolling and
platelet adhesion and aggregation. We hypothesized that ceramide induces vascular
inflammation and thrombosis in part by triggering Weibel-Palade body exocytosis.
Methods: We added ceramide to human aortic endothelial cells (HAEC) and assayed
Weibel-Palade body exocytosis by measuring the concentration of vWF released into the
media.
Results: Exogenous ceramide induces vWF release from endothelial cells in a dose-
dependent manner. As little as 10 nM ceramide induces a 50% maximal release of vWF.
Activators of endogenous ceramide production, neutral sphingomyelinase or tumor
necrosis factor-a (TNF-a), also induce Weibel-Palade body exocytosis. We next studied
the effects of nitric oxide (NO) on ceramide-induced Weibel-Palade body exocytosis,
since NO can inhibit vascular inflammation. The NO donor S-nitroso-penicillamine
(SNAP) decreases ceramide induced vWF release in a dose-dependent manner: the
IC50% for SNAP inhibition of vWF release is < 1 uM. In contrast, the NOS inhibitor L-
nitroarginine methyl ester (L-NAME) increases ceramide induced vWF release.
Conclusions: In summary, our findings show that endogenous ceramide triggers Weibel-
Palade body exocytosis, and that endogenous NO inhibits ceramide induced exocytosis.
These data suggest a novel mechanism by which ceramide induces vascular inflamma-
tion and thrombosis.
10:45 a.m.
841-2 Periadventitial Fat Inflammation Correlates With Plaque 
Inflammation in Patients With Coronary Plaque 
Ruptures: New Marker of Plaque Vulnerability?
Deborah Vela, Allen Burke, Alireza Zarrabi, Morteza Naghavi, Mohammad Madjid, Ward 
Casscells, III, Renu Virmani, James T. Willerson, Silvio Litovsky, Texas Heart Institute, 
Houston, TX, Armed Forces Institute of Pathology, Washington, DC
Background. Previous work from our laboratory showed the presence of significant
phagocytic activity in the aortic peri-adventitial fat of animal models of atherosclerosis
(apoE-deficient mice and Watanabe rabbits). The macrophage activity is only mild in the
aortic adventitial fat of wild-type mice and rabbits. In the present study we studied the
adventitial fat of human coronary arteries in patients with plaque ruptures and contrasted
them with those of patients with stable fibrocalcific plaques. We hypothesized that the
macrophagic density would be much greater in the former.
Table. Best ‘Univariate’ Predictors of Insulin Sensitivity
Parameter Estimate t Ratio Pr > t R2
Weight (kg) -0.020 -11.47 <0.0001 0.37
BMI -0.062 -12.77 <0.0001 0.40
Head % Fat -0.040 -12.52 <0.0001 0.41
Upper Body Fat (kg) -0.044 -12.50 <0.0001 0.41
Head Fat (kg) -0.807 -12.78 <0.0001 0.42
Waist (cm) -0.028 -13.38 <0.0001 0.42
* Age and gender were forced into every model.
